Literature DB >> 19562618

JAK2 V617F mutation is associated with 5q- syndrome in Chinese.

K F Wong1, W S Wong, Lisa L P Siu, T C Lau, N P Chan.   

Abstract

JAK2 V617F mutation is mostly seen in BCR-ABLI negative myeloproliferative neoplasms. Among other myeloid neoplasms, it occurs with remarkably high frequency in refractory anemia with ring sideroblasts associated with marked thrombocytosis, a group of myeloid neoplasms with both dysplastic and proliferative features. It has also been reported in occasional cases of myelodysplastic syndrome with isolated del(5q), often with a diagnosis of refractory cytopenia with multilineage dysplasia. We performed a retrospective analysis of JAK2 V617F mutation in Chinese patients with myeloid neoplasms and isolated del(5q), and were able to demonstrate the frequent occurrence of JAK2 V617F mutation in 5q- syndrome.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19562618     DOI: 10.1080/10428190903060103

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  3 in total

1.  Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes.

Authors:  Marta Fernandez-Mercado; Adam Burns; Andrea Pellagatti; Aristoteles Giagounidis; Ulrich Germing; Xabier Agirre; Felipe Prosper; Carlo Aul; Sally Killick; James S Wainscoat; Anna Schuh; Jacqueline Boultwood
Journal:  Haematologica       Date:  2013-07-05       Impact factor: 9.941

2.  Diagnosis of del(5q) MDS, 14 Years after JAK-2 Positive PV Appearance: Complete Remission of both Diseases with Lenalidomide Monotherapy.

Authors:  Antonella Vaccarino; Irene Dogliotti; Fabio Marletto; Andrea Demarchi; Mario Bazzan
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-10-20       Impact factor: 2.576

Review 3.  Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy.

Authors:  Pellegrino Musto; Vittorio Simeon; Roberto Guariglia; Gabriella Bianchino; Vitina Grieco; Filomena Nozza; Francesco La Rocca; Gioacchino Marziano; Anna Vittoria Lalinga; Emiliano Fabiani; Maria Teresa Voso; Patrizia Scaravaglio; Cristina Mecucci; Giovanni D'Arena
Journal:  Onco Targets Ther       Date:  2014-06-13       Impact factor: 4.147

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.